Literature DB >> 19261795

Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection.

Jooyun Lee, Gopi Patel, Shirish Huprikar, David P Calfee, Stephen G Jenkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19261795      PMCID： PMC2681849          DOI： 10.1128/JCM.02466-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  11 in total

Review 1.  Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

Authors:  Matthew E Falagas; Sofia K Kasiakou
Journal:  Clin Infect Dis       Date:  2005-03-22       Impact factor: 9.079

2.  In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis.

Authors:  Peter J Petersen; Ponpen Labthavikul; C Hal Jones; Patricia A Bradford
Journal:  J Antimicrob Chemother       Date:  2006-01-23       Impact factor: 5.790

3.  In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.

Authors:  Ellen S Moland; David W Craft; Seong-geun Hong; Soo-young Kim; Lucas Hachmeister; Shimon D Sayed; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

4.  Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.

Authors:  H Yigit; A M Queenan; G J Anderson; A Domenech-Sanchez; J W Biddle; C D Steward; S Alberti; K Bush; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster.

Authors:  Anastasia Antoniadou; Flora Kontopidou; Garifalia Poulakou; Evangelos Koratzanis; Irene Galani; Evangelos Papadomichelakis; Petros Kopterides; Maria Souli; Apostolos Armaganidis; Helen Giamarellou
Journal:  J Antimicrob Chemother       Date:  2007-02-16       Impact factor: 5.790

Review 6.  Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.

Authors:  Jian Li; Roger L Nation; Robert W Milne; John D Turnidge; Kingsley Coulthard
Journal:  Int J Antimicrob Agents       Date:  2005-01       Impact factor: 5.283

Review 7.  Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.

Authors:  Theodoros Kelesidis; Drosos E Karageorgopoulos; Iosif Kelesidis; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2008-08-01       Impact factor: 5.790

8.  Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.

Authors:  Mariana Castanheira; Hélio S Sader; Lalitagauri M Deshpande; Thomas R Fritsche; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

Review 9.  Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies.

Authors:  N Petrosillo; E Ioannidou; M E Falagas
Journal:  Clin Microbiol Infect       Date:  2008-09       Impact factor: 8.067

10.  Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study.

Authors:  Dimitrios K Matthaiou; Argyris Michalopoulos; Petros I Rafailidis; Drosos E Karageorgopoulos; Vassiliki Papaioannou; Georgia Ntani; George Samonis; Matthew E Falagas
Journal:  Crit Care Med       Date:  2008-03       Impact factor: 7.598
View more
  43 in total

1.  Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258.

Authors:  Tatiana Bogdanovich; Jennifer M Adams-Haduch; Guo-Bao Tian; Minh Hong Nguyen; Eun Jeong Kwak; Carlene A Muto; Yohei Doi
Journal:  Clin Infect Dis       Date:  2011-08       Impact factor: 9.079

2.  Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organisms from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug.

Authors:  Alexandre P Zavascki; Jian Li; Roger L Nation; Silvana V Superti; Afonso L Barth; Larissa Lutz; Fabiano Ramos; Márcio M Boniatti; Luciano Z Goldani
Journal:  J Clin Microbiol       Date:  2009-07-08       Impact factor: 5.948

3.  In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.

Authors:  Andrea Endimiani; Gopi Patel; Kristine M Hujer; Mahesh Swaminathan; Federico Perez; Louis B Rice; Michael R Jacobs; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

4.  In vitro potency of various polymyxin B components.

Authors:  Vincent H Tam; Henry Cao; Kimberly R Ledesma; Ming Hu
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

5.  In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates.

Authors:  Andrea Endimiani; Christopher Bethel; Yuvraj Choudhary; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2010-02-01       Impact factor: 5.191

6.  Independent emergence of colistin-resistant Enterobacteriaceae clinical isolates without colistin treatment.

Authors:  Shudan Chen; Fupin Hu; Xuelian Zhang; Xiaogang Xu; Yang Liu; Demei Zhu; Honghai Wang
Journal:  J Clin Microbiol       Date:  2011-09-07       Impact factor: 5.948

Review 7.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

8.  A Novel Deletion Mutation in pmrB Contributes to Concurrent Colistin Resistance in Carbapenem-Resistant Escherichia coli Sequence Type 405 of Clinical Origin.

Authors:  Ching-Hsun Wang; L Kristopher Siu; Feng-Yee Chang; Yu-Kuo Tsai; Yi-Tsung Lin; Sheng-Kang Chiu; Li-Yueh Huang; Jung-Chung Lin
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

9.  ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.

Authors:  Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Eliana S Armstrong; Yuvraj Choudhary; James B Aggen; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-10       Impact factor: 5.191

10.  Optimal therapy for multidrug-resistant Acinetobacter baumannii.

Authors:  Burke A Cunha
Journal:  Emerg Infect Dis       Date:  2010-01       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.